Michael Loftis is the founder of Ridgewood Capital Management LLC. His primary focus is value-oriented equity investing in the small and mid cap sectors. Michael is a former investment banker (Lehman Brothers and Barclays) and former M&A and securities law attorney (Mayer Brown and Keating Muething & Klekamp).
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Michael Kramer is the founder and PM of MCM.
Michael Kramer is a thematic growth investor. He likes to think about themes in society and find long term equity investments that fit those themes.
Michael is the founding member of Mott Capital Management, LLC in 2014. Prior to MCM Michael spent the previous 10 years working as a domestic and international equity trader. During this time he was responsible for handling trades in some of the most illiquid equities. Additionally, Michael has experience trading in some of the most exotic foreign markets.
Mott Capital Management is a Thematic Growth investor using themes and trends in life to find exciting growth stories. Once we find a theme we want to capitalize on we begin searching for products that interact with the end user. From there we begin the company search process. We are long-term because that is our edge. We understand and recognize when events are critical and when they are not. We also believe it is a way to neutralize market volatility.
The Clinically Sound Investor is a pharmacist with a PharmD and a BA in psychology. He has worked across the spectrum from very small independent and hospital pharmacies to the some of the largest retail corporations and medical centers in the nation, as well as experience in specialty and mail order settings. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results. His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
Four private female investors and one Dachshund.
We've consigned our careers as fund managers to the trashcan, as we no longer have confidence that we can grow our clients' money anywhere near approaching the sparkling results that we achieved for them in the past.
Now Heidi and Desiree's interests are in the fields of global water distribution, agriculture, and timberland, while Clarissa and Helga manage strategies of certain hard assets, predominantly the PGM metals group.
All four of us enjoy the heady barrage of marriage proposals and death threats we've been receiving since we started commenting on Seeking Alpha. That's why we continually try to both titilate and irritate readers with our sweet and innocent commentary. We also started posting Instablogs with absolutely essential information that investors just can't live without. Check them out (at your peril...)
Oh. And while our names (Heidi, Helga, Clarissa and Desiree) may not be our real names, Schnitzel the Dachshund's name really is "Schnitzel the Dachshund."
I invest (technically) part-time, but I love the markets and immerse myself in them daily. I enjoy writing about my investment ideas as it helps me to organize my thoughts and I am happy to share if it helps others. I invite criticism as it will help sharpen my ideas, so please tell me where, in your opinion, I am going wrong.
Master in Applied Maths & Computer Science from Moscow State University. MA in Economics from New Economic School, Moscow, Russia. CFA Charterholder.
First 3 years - sell side research (first equity, then fixed income).
Next 3 years - buy side, equity & HFs (first analyst, then fund manager).
Ever since - Private Banking, all asset classes, fund selection, FoF manager, ETF strategies; some single stock mandates and M&A advisory (biotech/pharma, IT, resource juniors).
Renaissance Investment Management, HSBC, Raiffeisenbank Austria. Currently PM at Leon Multi-Family Office (Russia/Cyprus).
Retail Investor, Shareholder Advocate and Editor of Stocks DD blog. You are cautioned to read the disclaimer in Seeking Alpha before reading my articles. I am NOT a registered investment adviser. My articles are ONLY for informative purposes and should NOT be treated as investment advice.
My investment philosophy:
1. Invest in Strong businesses (high barriers to entry) 2. Invest in Management with excellent track record for shareholder value creation 3. Invest at undervalued prices
Invest in special situations (bankruptcy or other restructuring) or Drug development firms, where there is with an asymmetric reward/risk...where I have strong conviction on a reward event.
I am also interested in the shareholders topics in publicly listed companies:
1. Shareholder rights 2. Giving shareholders a voice incl shareholder participation in value creation 3. Improving board and management's accountability to shareholders
Be a shareholder advocate and work towards insuring boards and management "do the right thing for shareholders", maximizing and protecting shareholder's value.
More on my ideas can be found here:
*************Original User account: 17741882***********************
General : Aspiring Equity Analyst with 7 years of professional and personal investment experience. Primary focus is Value and Growth both domestic and abroad (Europe and Latin America)
Professional Experience: Hedge Fund Assurance and Valuation Services ( AUM 100M - 10B). Exposure to almost every investment strategy and product on the market. Strategies ranged from typical Long/Short Equity & Structured Products such as MBS and CDOs, all the way to reinsurance funds trading catastrophe linked bonds.
Licenses: CPA (NJ) Certified Public Accountant
CFA Candidate - Level 1 June 2017
Very proud Rutgers Graduate- New Brunswick Campus - GO Scarlet Knights ! -
Major: Bachelor's of Accounting
SevenSeas Investment Research was created to provide investors with honest, deeply considered, detailed, passionately conducted, straight forward, value focused, fundamental investment research on a variety of asset classes and market topics.
I use a combination of traditional value focused fundamental research and a proprietary method of stock selection that can be adjusted to meet a dynamic mixture of different risk tolerances, and various other investor criteria to construct concentrated and unique portfolios to any given individual's investment needs.
My deep knowledge of Alternative Investments and Accounting (both GAAP & IFRS), as well as my exposure to dozens of successful hedge fund portfolios and complex investment securities, provided me with a unique perspective few obtain of a side of the market unseen by the retail investor. I wish to share my passion and knowledge for the markets that has grown to an obsession over the last 7 years with the SA community, to bring value to investors ranging from beginners, all the way to seasoned professionals, and network with the thousands of talented individuals from around the world who come to the platform seeking the same objectives.
My overall mission is to provide readers with valuable research to assist them in making wise investment decisions. All articles are my own personal views, and do not constitute investment advice. **Please be sure to contact your own investment professional when considering purchasing an investment.
SevenSeas will remain dedicated to providing a complete, and consistent level of work and appreciation for the readers. The highest standards of ethics and professionalism will be displayed at all times. I welcome all feedback and can be reached via direct messaging. Best of luck to all, and I hope you enjoy the work.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha). Licensed Investment Advisor. Top-ranked analyst on Tipranks.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
David Sims is the managing member of RidgeHaven Capital LLC. We prefer distressed equities and value investing. The firm was established to manage wealth with an eye on fundamental value, but also an understanding of technical trends and market behavior.
David is a Certified Public Accountant and previously worked as an auditor at a Big 4 accounting firm, SEC Reporting Analyst and financial systems administrator at a small private company.
Find the Sims On Finance Investing Podcast on iTunes, Tune In Radio, and Player FM radio.
BRIAN K. LANGENBERG, CFA is a strategic thinker, team builder and expert in global manufacturing, machinery, logistics and distribution. He is a trusted advisor to CEOs and other executives of public and private companies, institutional investors and high net worth individuals because of his intellectual integrity and unsurpassed ability to ignore herd mentality, think outside the box and deliver an honest, unfiltered assessment of the question at hand. In other words – he tells it like it is – and before others figure it out.
Brian supports American manufacturing as a path to prosperity. Every U.S. manufacturing job supports 5-7 more.
Labor deserves fair treatment, starting with their children’s education. Brian supports 100% school choice. Chicago spent $16,400 per student in 2015 (ridiculous). EVERY parent picks the school or hires a tutor and 90% of those funds go to the school/teacher, CPS keeps 10% to monitor outcomes/delivery. Schools failing to attract students close and teachers lose jobs. Period. Two single moms w/6 kids can hire a (good) teacher directly in a safe environment.
College – no more bartenders with $40K in debt. Require incoming students get school specific employment and comp data, by major, before they pay/enroll.
Capital – Cut U.S. corporate tax rate to 20%, rein in government and corruption and jobs flood back.
Langenberg & Company provides strategic and financial advisory services to a range of private and public companies, institutional equity research and subscription products for corporate executives, small manufacturers and retail investors.
Contact directly at Brian@Langenberg-llc.com to inquire.
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and is now known as Aralez Pharmaceuticals (Nasdaq: ARLZ). He is currently on the board of directors of both Select Sands Corp. (TSX.V: SNS.V) as well as Comstock Metals Ltd. (TSX.V: CSL.V) which both trade on the TSX Venture exchange.
Arthur Baer is founder and Chief Investment Officer of Cavendish Fund Management LLC a fundamental focused long/short equity fund. Mr. Baer was previously Chief Financial Officer and Vice Chairman of Brite Media Group LLC from January 2005 to April 2014. BMG was a media and marketing company that was founded in 2005 and backed by a private equity firm. Mr. Baer previously worked for Lehman Brothers in the investment banking division. Mr. Baer graduated from Georgetown University with a Bachelor of Science in Business Administration with a major in finance.
Looking for blatant mispricing typically under $1bn market cap -- in either direction, with a short bias. L/S equity fund analyst. Passed all levels of the CFA program; MBA in finance from a top-5 school.
I am professionally a real estate lender/investor in mortgage workouts in distress. My edge is an area undiscovered, not easy to move around more than a few million at a time and is largely a fragmented, although after 8 years of stimulus, value is becoming scarce. Recreationally, I am a private pilot, sailor and skier. I speak some Japanese and Spanish and have lived and worked on most continents. I manage friends and family self directed 401K's, IRA's, and HSA's as well as my company investments. About 80% of my net worth is in mortgages or real estate, the remaining is in public exchanges.
MBA student at the Wharton School, WG '18. Formerly summer hedge fund analyst at Rangeley Capital, focusing on value and event-driven investing. Former investment banking analyst at Goldman Sachs and Business Operations at LinkedIn. Graduated magna cum laude in Applied Mathematics from Harvard. Interested in value and event-driven investing.